Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12624039 | 0.83 | MC4R (0.44) | KMT2AMEN1ALDH1A1EPHX2DDB1 | |
| SCHEMBL12624010 | 0.78 | OPRL1 (0.48) | ALDH1A1SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL12624028 | 0.77 | SLC6A9 (0.47) | ALDH1A1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17608923 | 0.75 | ALDH1A1 (0.52) | KMT2AMEN1ALDH1A1CYP2C9TSHR | |
| SCHEMBL20989974 | 0.75 | OPRM1 (0.36) | KMT2AMEN1ALDH1A1CYP2C9TSHR | |
| SCHEMBL12626443 | 0.74 | KDM1A (0.48) | ALDH1A1TSHRCYP2C19CYP2D6 | |
| SCHEMBL4315750 | 0.74 | HSD17B10 (0.55) | ALDH1A1TSHRCYP2C19HIF1ACYP2D6 | |
| SCHEMBL13543071 | 0.73 | HSD17B10 (0.58) | KMT2AMEN1ALDH1A1CYP2C9TSHR | |
| SCHEMBL12627091 | 0.73 | OPRD1 (0.55) | TSHROPRD1OPRK1 | |
| SCHEMBL12621911 | 0.72 | CYP2D6 (0.43) | KMT2AMEN1ALDH1A1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11385221-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022098700-A1 | INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4 | CASSAVA SCIENCES, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20210389298-A1 | Alzheimer's Disease Assay in a Living Patient | PAIN THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3791875-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | Cassava Science, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3054956-B1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20190271686-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-7589207-B2 | Cyclohexyl compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589207-B2 | Cyclohexyl compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | AQUINO CHRISTOPHER JOSEPH | 2009-02-26 | — | — | US | disclosed |
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | AQUINO CHRISTOPHER JOSEPH | 2009-02-26 | — | — | US | disclosed |
| US-7452992-B2 | inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS); 1-((1R,5S)-8-{2-[3-(2,2-dimethylpropanoyl)-6-phenyl-1,3-oxazinan-6-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452992-B2 | inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS); 1-((1R,5S)-8-{2-[3-(2,2-dimethylpropanoyl)-6-phenyl-1,3-oxazinan-6-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR1 | KMT2A 4579/4885MEN1 4508/4885ALDH1A1 2775/4885 |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | KMT2A 1560/4885MEN1 2287/4885ALDH1A1 4388/4885 |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | KMT2A 1560/4885MEN1 2287/4885ALDH1A1 4388/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | KMT2A 1560/4885MEN1 2287/4885ALDH1A1 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.